Trial Profile
A Phase 2, Randomized, Open-Label, Safety and Dose-Finding Study Comparing 3 Different Doses of Weekly TV-1106 and Daily Recombinant Human Growth Hormone Therapy in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Albusomatropin (Primary) ; Somatropin
- Indications Somatotropin deficiency
- Focus Therapeutic Use
- Sponsors Teva Pharmaceutical Industries
- 19 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Aug 2016.
- 08 Jun 2016 Planned End Date changed from 1 Jun 2016 to 1 Jul 2016.
- 04 May 2016 Planned End Date changed from 1 Apr 2016 to 1 Jun 2016.